Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Terminated Phase 2 Interventional Results available

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

NCT05814666
View directory record Official record
Conditions
HNSCC
Interventions
Danvatirsen, Pembrolizumab
Drug
Lead sponsor
Flamingo Therapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Irvine, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

NCT02737722
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
Bisphosphocin Nu-3, Placebo
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
San Francisco, California • Oldsmar, Florida • Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

NCT02436824
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
AB001 patch, Placebo patch
Drug · Other
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Miami, Florida • Naples, Florida • Marietta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

NCT00002170
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Diego, California • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

NCT00853580
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Lovastatin ™, placebo
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 15 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

CT 327 in the Treatment of Psoriasis Vulgaris

NCT00995969
View directory record Official record
Conditions
Psoriasis
Interventions
placebo, CT 327
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 23, 2026, 5:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

NCT04068610
View directory record Official record
Conditions
Metastatic Microsatellite-stable Colorectal Cancer
Interventions
Durvalumab, Oleclumab, FOLFOX, Bevacizumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Study of U101 for Bladder Pain and/or Urgency

NCT00256542
View directory record Official record
Conditions
Pelvic Pain, Interstitial Cystitis, Bladder Diseases
Interventions
Alkalinized Lidocaine-Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
9
States / cities
San Diego, California • Cartersville, Georgia • Centralia, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2006 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

NCT04343573
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

NCT06158620
View directory record Official record
Conditions
Post Operative Pain, Urolithiasis, Ureter Calculi, Stent Complication
Interventions
intra-nasal ketorolac, oral diclofenac
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

NCT01748942
View directory record Official record
Conditions
Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions
Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 23, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

NCT01515046
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Gemcitabine with escalating ascorbic acid
Drug
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

NCT00642642
View directory record Official record
Conditions
Acne Scarring of the Face
Interventions
Autologous Human Fibroblasts (azficel-T), Placebo
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • San Diego, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

NCT04251910
View directory record Official record
Conditions
Agitation,Psychomotor, Dementia
Interventions
Sublingual film containing Dexmedetomidine, Sublingual Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Homestead, Florida • Miami Lakes, Florida • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional

Sirolimus in Treating Patients With Glioblastoma Multiforme

NCT00047073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Rapamycin, Surgery, Supportive Care
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00817778
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 23, 2026, 5:51 AM EDT
Not yet recruiting Not applicable Interventional

OCM™ Treatment With Routine Care in Venous Leg Ulcers Compared to Routine Care Treatment Alone.

NCT07754526
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 5:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers

NCT04062552
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Behavioral, Psychological or Informational Intervention, Educational Intervention, Medical Examination Assessment, Quality-of-Life Assessment, Survey Administration, Telephone-Based Intervention
Other · Procedure · Behavioral
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
113
States / cities
Fort Smith, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 23, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

NCT01781468
View directory record Official record
Conditions
Fatigue
Interventions
armodafinil 150 mg, Placebo, armodafinil 250 mg
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
365
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 23, 2026, 5:51 AM EDT